Michael Tomsicek
Director/Board Member at MILESTONE PHARMACEUTICALS INC.
Net worth: 82 835 $ as of 31/03/2024
Profile
Mr. Michael J. Tomsicek is an Independent Non-Executive Director at Milestone Pharmaceuticals, Inc. and a CFO & Principal Accounting Officer at CRISPR Therapeutics AG. He is on the Board of Directors at Milestone Pharmaceuticals, Inc. and Optimer Pharmaceuticals LLC. Mr. Tomsicek was previously employed as a CFO, Treasurer, Principal Accounting Officer & VP by ABIOMED, Inc., a Treasurer by Cubist Pharmaceuticals, Inc., a CFO-Global Ultrasound Product Group by General Electric Healthcare Technologies, Inc., a Manager-Commercial Finance & Business Planning by Motorola Automotive & Industrial Electronics Group, and a Chief Financial Officer by The Lexington. He also served on the board at Trius Therapeutics, Inc. He received his undergraduate degree from the University of Wisconsin and an MBA from the University of Wisconsin.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 24/04/2023 | 7,830 ( 0.03% ) | 55 985 $ | 31/03/2024 | |
| 07/06/2023 | 15,000 ( 0.03% ) | 26 850 $ | 31/03/2024 |
Michael Tomsicek active positions
| Companies | Position | Start |
|---|---|---|
| MILESTONE PHARMACEUTICALS INC. | Director/Board Member | 01/04/2019 |
| ACRIVON THERAPEUTICS, INC. | Director/Board Member | 01/10/2022 |
Optimer Pharmaceuticals LLC
 Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | Director/Board Member | 24/10/2013 |
Cimeio Therapeutics AG
 Cimeio Therapeutics AG Packaged SoftwareTechnology Services Cimeio Therapeutics AG is an applied gene editing and immunotherapy company based in Basel, Switzerland. Cimeio is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip) that have the potential to transform hematopoietic stem cell transplant. The Swiss company's technology platform is based on the design and expression of modified variants of naturally occurring cell surface proteins in hscs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. Cimeio is the leader of the field of epitope editing and is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip), novel immunotherapies which have the potential to transform treatment of hematologic diseases. The company develops state-of-the-art immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in hscs. These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. The company was founded by Lukas Jeker and the CEO is Thomas Fuchs. | Director/Board Member | 03/11/2022 |
Former positions of Michael Tomsicek
| Companies | Position | End |
|---|---|---|
| CRISPR THERAPEUTICS AG | Director of Finance/CFO | 14/10/2021 |
| ABIOMED, INC. | Director of Finance/CFO | 24/08/2017 |
| CUBIST PHARMACEUTICALS INC | Director of Finance/CFO | 01/01/2015 |
General Electric Healthcare Technologies, Inc.
 General Electric Healthcare Technologies, Inc. Medical/Nursing ServicesHealth Services General Electric Healthcare Technologies, Inc. provides transformational medical technologies and services. The company is headquartered in Houston, TX. | Corporate Officer/Principal | 01/09/2010 |
The Lexington
 The Lexington Medical/Nursing ServicesHealth Services Part of The Ensign Group, Inc., The Lexington operates a 125-bed assisted living facility. The private company is based in Ventura, CA. | Director of Finance/CFO | - |
Training of Michael Tomsicek
| University of Wisconsin | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| MILESTONE PHARMACEUTICALS INC. | Health Technology |
| CRISPR THERAPEUTICS AG | Health Technology |
| ACRIVON THERAPEUTICS, INC. | Health Technology |
| Private companies | 8 |
|---|---|
ABIOMED, Inc.
 ABIOMED, Inc. Medical SpecialtiesHealth Technology ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded by David M. Lederman in 1981 and is headquartered in Danvers, MA. | Health Technology |
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | Health Technology |
Trius Therapeutics, Inc.
 Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
General Electric Healthcare Technologies, Inc.
General Electric Healthcare Technologies, Inc. Medical/Nursing ServicesHealth Services General Electric Healthcare Technologies, Inc. provides transformational medical technologies and services. The company is headquartered in Houston, TX. | Health Services |
The Lexington
The Lexington Medical/Nursing ServicesHealth Services Part of The Ensign Group, Inc., The Lexington operates a 125-bed assisted living facility. The private company is based in Ventura, CA. | Health Services |
| Motorola Automotive & Industrial Electronics Group | |
Cimeio Therapeutics AG
Cimeio Therapeutics AG Packaged SoftwareTechnology Services Cimeio Therapeutics AG is an applied gene editing and immunotherapy company based in Basel, Switzerland. Cimeio is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip) that have the potential to transform hematopoietic stem cell transplant. The Swiss company's technology platform is based on the design and expression of modified variants of naturally occurring cell surface proteins in hscs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. Cimeio is the leader of the field of epitope editing and is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip), novel immunotherapies which have the potential to transform treatment of hematologic diseases. The company develops state-of-the-art immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in hscs. These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. The company was founded by Lukas Jeker and the CEO is Thomas Fuchs. | Technology Services |
- Stock Market
- Insiders
- Michael Tomsicek
